Inhaled Nitric Oxide Delivery: Past, Present, and Future
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.
Category: Pulmonary Hypertension
Pulmonary Hypertension
Latest
Pulmonary Hypertension
Latest
Inhaled Nitric Oxide in Cardiovascular Surgery for Perioperative Pulmonary Hypertension: A Review
Clinical trial and real-world data provide evidence that inhaled nitric oxide is effective for reducing pulmonary hypertension in the perioperative setting.
Pulmonary Hypertension
Latest
Pulmonary Hypertension Patients Exhibited Reduced Exercise Capacity Under Hypoxia
Results of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
Better Risk Calculator for Pulmonary Arterial Hypertension
For patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read More
Pulmonary Arterial Hypertension Treatment With Macitentan Is Safe and Effective for Patients With Systemic Sclerosis
Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read More
Pulmonary Arterial Hypertension Patients Benefit from Macitentan + Tadalafil Combo
Patients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read More
No Benefit for Idiopathic Interstitial Pneumonia-associated PH Patients Treated with Adempas
For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag Functionally Improves Pulmonary Hypertension Patients with COPD
Selexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreSevere OSA Tied to Higher BP in Resistant Hypertension
In obstructive sleep apnea patients with high blood pressure resistant to treatment, the more severe their OSA, the higher their blood pressure.
Read MoreNew Drug Target Discovered for the Lung Disease PAH
Scientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read More
Pulmonary Arterial Hypertension Device Receives FDA Breakthrough Designation
SoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).
Read More
Cardiac MRI May Lead to Targeted PAH Therapy
Patients at greatest risk of dying from PAH may be identified through cardiac MRI and the information the noninvasive scan provides about the functional level of the heart’s right ventricle.
Read More
Tumor-suppressing Protein May Be Novel Target in PAH Therapy
In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read More
Selexipag Improved Clinical Outcomes in Pulmonary Arterial Hypertension
Treatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read More
Pulmonary Arterial Hypertension Tied to Protein Production
Development of pulmonary arterial hypertension (PAH) may be related to increased production of Nestin protein in the pulmonary vasculature, a Plos One study reports.
Read More